Clinical trial
Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
NCT00268970 · Agennix, Industry · Completed
Key facts
| NCT number | NCT00268970 |
|---|---|
| Title | Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer |
| Official title | Phase 2 Trial of First-Line Therapy With Satraplatin and Paclitaxel in Patients With Unresectable Stage III or IV Non-small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Agennix, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Satraplatin in combination with Paclitaxel |
| Enrollment | 40 |
| Start date | Dec 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Sep 1, 2009 |
| First posted | Dec 23, 2005 |
| Last update posted | Apr 30, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: